BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34459887)

  • 1. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
    Stasik S; Eckardt JN; Kramer M; Röllig C; Krämer A; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause S; Herbst R; Hänel M; Frickhofen N; Noppeney R; Kaiser U; Baldus CD; Kaufmann M; Rácil Z; Platzbecker U; Berdel WE; Mayer J; Serve H; Müller-Tidow C; Ehninger G; Bornhäuser M; Schetelig J; Middeke JM; Thiede C;
    Blood Adv; 2021 Sep; 5(17):3279-3289. PubMed ID: 34459887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation.
    Liu J; Qin W; Wang B; Wang Z; Hua H; Zhou F; Jia Z; Wu P; Chao H; Lu X
    Leuk Res; 2022 Jul; 118():106859. PubMed ID: 35617714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China.
    Yang J; Zhao L; Wu Y; Niu T; Gong Y; Chen X; Huang X; Liu J; Dai Y; Ma H
    Cancer Med; 2023 Dec; 12(23):21111-21117. PubMed ID: 37937729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
    Alfayez M; Issa GC; Patel KP; Wang F; Wang X; Short NJ; Cortes JE; Kadia T; Ravandi F; Pierce S; Assi R; Garcia-Manero G; DiNardo CD; Daver N; Pemmaraju N; Kantarjian H; Borthakur G
    Leukemia; 2021 Mar; 35(3):691-700. PubMed ID: 32561839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia.
    Fobare S; Kohlschmidt J; Ozer HG; Mrózek K; Nicolet D; Mims AS; Garzon R; Blachly JS; Orwick S; Carroll AJ; Stone RM; Wang ES; Kolitz JE; Powell BL; Oakes CC; Eisfeld AK; Hertlein E; Byrd JC
    Blood Adv; 2022 Mar; 6(5):1371-1380. PubMed ID: 34847232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and prognostic analysis of acute myeloid leukemia patients with PTPN11 mutations.
    Sun Y; Zhang F; Huo L; Cai W; Wang Q; Wen L; Yan L; Shen H; Xu X; Chen S
    Hematology; 2022 Dec; 27(1):1184-1190. PubMed ID: 36318614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of Coexisting Gene with NRAS in Acute Myeloid Leukemia].
    Sheng YP; Hua HY; Chao HY; Zhu WY; Wang ZQ; Zhang Y; Zhou Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):351-356. PubMed ID: 35395962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of DNMT3A variant allele frequency and two different comutations on patients with de novo cytogenetically normal acute myeloid leukemia.
    Chen X; Tian C; Hao Z; Pan L; Hong M; Wei W; Muyey DM; Wang H; Chen X
    Cancer Med; 2023 May; 12(9):10340-10350. PubMed ID: 36912186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
    Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical Significance of RAS Gene Mutations in Patients with Acute Myeloid Leukemia].
    Wei JF; Qiu HY; Chen Z; Miao L; Wang Y; Zhao LD; Cai ZM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1391-1396. PubMed ID: 36208240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
    Gaidzik VI; Schlenk RF; Paschka P; Stölzle A; Späth D; Kuendgen A; von Lilienfeld-Toal M; Brugger W; Derigs HG; Kremers S; Greil R; Raghavachar A; Ringhoffer M; Salih HR; Wattad M; Kirchen HG; Runde V; Heil G; Petzer AL; Girschikofsky M; Heuser M; Kayser S; Goehring G; Teleanu MV; Schlegelberger B; Ganser A; Krauter J; Bullinger L; Döhner H; Döhner K
    Blood; 2013 Jun; 121(23):4769-77. PubMed ID: 23632886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
    Wakita S; Marumo A; Morita K; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Nakayama K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Tashiro H; Sakaguchi M; Yui S; Arai K; Kitano T; Miyata M; Arai H; Kanda M; Itabashi K; Fukuda T; Kanda Y; Yamaguchi H
    Cancer Sci; 2023 Apr; 114(4):1297-1308. PubMed ID: 36610002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the clinical characteristics and prognosis of adult
    Sheng L; Liu Y; Zhu Y; Zhou J; Hua H
    Open Med (Wars); 2023; 18(1):20230830. PubMed ID: 38025540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
    Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
    J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
    Wang R; Gao X; Yu L
    BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications.
    Hou HA; Kuo YY; Liu CY; Chou WC; Lee MC; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
    Blood; 2012 Jan; 119(2):559-68. PubMed ID: 22077061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML.
    Narayanan D; Pozdnyakova O; Hasserjian RP; Patel SS; Weinberg OK
    Blood Adv; 2021 Jun; 5(11):2539-2549. PubMed ID: 34100902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.